Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI),
stroke, or death from an MI or stroke in patients with abdominal obesity with other
cardiovascular (CV) risk factors.
The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV
death, or CV hospitalization in these patients.